Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page shows a small revision update from v3.4.1 to v3.4.2 with no obvious changes to study details or page behavior. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0, indicating a minor document version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check31 days agoChange DetectedMinor UI/metadata updates include a new 'Show glossary' option, capitalization tweaks to QC-related labels (e.g., 'Last Update Submitted that Met QC Criteria'), and a revision from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedLocations sections now list individual sites and regions instead of grouped 'Locations' headings. The update adds numerous sites across the US, Canada, Europe, and Australia (e.g., Arizona, Ontario, The Netherlands, New South Wales, Victoria).SummaryDifference2%

- Check89 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2; no changes to study content or page layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.